Skip to content

Mind Programme for Women With Breast Cancer

Mind Programme for Women With Breast Cancer: A Randomized Controlled Trial Testing the Programme´s Cost-effectiveness and Efficacy in Changing Psychological and Biological Outcomes

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05642897
Acronym
MIND
Enrollment
150
Registered
2022-12-08
Start date
2023-01-02
Completion date
2025-08-31
Last updated
2024-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Female

Keywords

Mindfulness, Compassion Focused Therapy, Acceptance and Commitment Therapy, biological markers, cost-effectiveness, mental health

Brief summary

The Mind programme for cancer patients was developed by this project PI through the integration of ACT, mindfulness and CFT components specifically adapted to the needs of a cancer population. This intervention aims at improving well-being, preventing subsequent distress, and promoting adaptation to the disease and posttreatment period. A recent pilot study presented preliminary findings on this intervention, suggesting high acceptability and efficacy in improving self-reported psychological health in breast cancer patients undergoing Radiotherapy treatment. Nevertheless, this study's small sample size, methodology (inactive control group), and exclusive reliance on self-reported data limit the interpretation and generalization of results, creating an avenue for the optimization and further testing of the programme through more robust and reliable methods. The aim of this project is therefore to optimize the Mind programme taking into consideration the results from its pilot study and to conduct a Randomized Controlled Trial on the efficacy of the intervention in improving not only mental health outcomes but also biological markers, as well as on its cost-effectiveness, in women with breast cancer. The superiority of the Mind programme will be compared to a support group intervention through the analysis of changes in cancer-specific quality of life, depressive symptoms and anxiety severity, psychological experiences, and immunological and epigenetics markers related to mental health and breast cancer prognosis. All participants will receive the intervention that shows better results.

Interventions

BEHAVIORALMind

ACT, mindfulness, and compassion-based intervention

BEHAVIORALSupport Group

This intervention promotes the sharing of cancer-related experiences, active listening and a sense of community between participants.

Sponsors

IPATIMUP - Instituto De Patologia E Imunologia Molecular Da Universidade Do Porto
CollaboratorOTHER
University of Coimbra
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

1. age between 18-70; 2. primary diagnosis of BC (stages between I and III); 3. undergoing radiotherapy treatment at CHUC; 4. able to understand and answer to self-report questionnaires in Portuguese.

Exclusion criteria

1. currently undergoing any form of psychological intervention; 2. current diagnosis of severe psychiatric illness (psychotic disorder, bipolar disorder, substance abuse, and personality disorder) or suicidal ideation; 3. diagnosis of neurological disease.

Design outcomes

Primary

MeasureTime frameDescription
Cancer-specific quality of lifeBaseline, post-treatment (2 months after baseline), and 6-months follow-upEORTC QLQ-C30 - Quality of Life, the higher the score, the higher the QoL level

Secondary

MeasureTime frameDescription
Self-compassion and mindfulnessBaseline, post-treatment (2 months after baseline), and 6-months follow-upSelf-compassion Scale, the higher the score, the higher the self-compassion or mindfulness level
Immunological and epigenetic markersBaseline, post-treatment (2 months after baseline) and 6-months follow-upImmunology indicators. Inflammatory biomarkers formerly associated with depression and anxiety (e.g., CRP, IL-6 and TNFalpha); biomarkers of the development of effective immune surveillance (e.g., IFNgamma, IL-12/18, GM-CSF); suppressive cytokines that may block the development of effective anti-tumour immune responses (e.g., IL-10, IL-4/13). Epigenetics indicators. Expression of miRs associated with stress response, inflammation, or BC prognosis (miR-21, miR-146a, miR-155, and miR-Let7).
General quality of lifeBaseline, post-treatment (2 months after baseline), and 6-months follow-upEQ-5D-5L, the higher the score, the higher the QoL level
Psychological flexibilityBaseline, post-treatment (2 months after baseline), and 6-months follow-upComprehensive Assessment of Acceptance and Commitment Therapy's Processes, the higher the score, the higher psychological flexibility level
ACT processes (Hexa(in)Flex Interview)BaselineHexa(in)Flex Interview is a semi-structured interview that aims to assess qualitatively the subjective experience of the 6 core processes of the Psychological (In)Flexibility Model underlying ACT in women with breast cancer. The interview has two parts: 1) an introduction to the aims of the interview, as well as introductory questions regarding diagnostic information (e.g., duration of diagnosis, treatment phase, support network) and general coping and adaptation to the cancer diagnosis; 2) Five sections of open questions aiming to assess: experiential avoidance versus acceptance, cognitive fusion versus defusion, conceptual versus contextual self, Past and future conceptualized (auto-pilot) versus contact with present moment, and lack of values clarity and action versus commitment to valued action. Each section has instructions on how the interviewer should conduct the questioning, as well as additional tips and caveats that should be considered.
Consumption of resources and costsBaseline, post-treatment (2 months after baseline), and 6-months follow-upTo collect data regarding resources used by participants outside the hospital setting, the research team developed a questionnaire adapted from the UK Cancer Costs Questionnaire (UKCC) Version 2.0 (http://blogs.ed.ac.uk/ukcc). Hospital costs will be taken from clinical registries.
Depressive symptoms and anxiety severityBaseline, post-treatment (2 months after baseline), and 6-months follow-upHADS, the higher the score, the higher anxiety and depression level
Major life events questionnaire - controlling variable6-months follow-upMajor Life Event Questionnaire, the higher the score, the higher the number of major life events in the previous year

Countries

Portugal

Contacts

Primary ContactInês A Trindade, PhD
ines.almeidatrindade@gmail.com239851450
Backup ContactHelena Moreira, PhD
hmoreira@fpce.uc.pt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026